Feb 12, 2016

HeartWare Schedules Fourth Quarter 2015 Financial Results Conference Call And Webcast

HeartWare International, Inc. (NASDAQ: HTWR) has scheduled a conference call and webcast to discuss its financial results for the three and 12 months ended December 31, 2015, on Thursday, February...

FRAMINGHAM, Mass.Feb. 12, 2016 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR) has scheduled a conference call and webcast to discuss its financial results for the three and 12 months ended December 31, 2015, on Thursday, February 25, 2016 at 8:00 a.m. ET.  The company plans to release the financial results prior to the conference call and webcast.  On the conference call and webcast, management will discuss the company's financial results, highlights from the fourth quarter and business outlook.  

The conference call may be accessed by dialing 1-877-407-0789 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-201-689-8562.

The live webcast will be available from the Investors section of the company's website (http://ir.heartware.com/).  A replay will be available through the above link immediately following completion of the call.

A copy of the news release announcing the financial results and related information will be available on the company's website, www.heartware.com.

About HeartWare International

HeartWare International, Inc. develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare HVAD System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 47 countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit www.heartware.com.  

Contact:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartware.com 
Phone: +1 508 739 0864

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/heartware-schedules-fourth-quarter-2015-financial-results-conference-call-and-webcast-300219397.html

SOURCE HeartWare International, Inc.